NEW YORK, NY – [Date of Publication, e.g., August 15, 2026] – In a monumental stride forward for assistive technology, Wandercraft, a pioneer in advanced robotics, has announced that its personal self-balancing exoskeleton, Eve, has received clearance from the U.S. Food and Drug Administration (FDA). This landmark decision is poised to revolutionize upright mobility for eligible wheelchair users, extending the benefits of standing and walking from specialized rehabilitation settings directly into the fabric of daily life.
Eve represents a profound shift in personal mobility solutions, offering a hands-free, self-balancing system designed to support individuals with spinal cord injuries in performing everyday activities. The clearance signifies not just a regulatory approval, but a beacon of hope for countless individuals seeking greater independence and a return to the "ordinary moments that may hold extraordinary meaning." This innovative device is intended for use on level indoor surfaces and immediately adjacent open-air areas like patios and terraces, under the supervision of a specially trained companion, enabling users to engage with their world from a new, upright perspective.
Main Facts: Redefining Upright Mobility
The FDA clearance for Wandercraft’s Eve marks a pivotal moment in the evolution of personal assistive devices. Unlike previous exoskeletons primarily confined to clinical rehabilitation, Eve is specifically engineered for personal use, bringing the transformative experience of upright mobility into the home and community. This hands-free, self-balancing system targets eligible adults living with spinal cord injuries at any level, empowering them to walk, bend, turn, and utilize their hands while standing – activities that have largely been inaccessible for many.
Eve is not designed to replace wheelchairs but rather to complement them, offering expanded opportunities for engagement in daily life. From reaching items on a high shelf to conversing eye-to-eye with friends and family, the potential for enhanced quality of life is immense. The device’s core innovation lies in its advanced self-balancing technology, which negates the need for crutches or other external supports, freeing the user’s hands for interaction with their environment. This feature is a direct evolution from Wandercraft’s experience with its rehabilitation exoskeleton, Atalante X, which has been deployed in over 150 rehabilitation and research centers globally, laying the groundwork for Eve’s groundbreaking capabilities.
The commercial launch of Eve in the United States is slated for September 17, 2026, a date anticipated with great excitement by the disability community, clinicians, and robotics enthusiasts alike. The official unveiling will take place at an exclusive event at the Cure healthcare innovation campus in New York City, presented in collaboration with the United Spinal Association, which will be celebrating its 80th anniversary. This livestreamed program will serve as a global platform to showcase the transition of self-balancing exoskeleton technology from a clinical tool to a personal mobility solution, bringing together users, caregivers, researchers, and policymakers to witness this historic occasion.
Chronology: A Journey to Everyday Mobility
Wandercraft’s journey to the FDA clearance of Eve is a testament to years of dedicated research, development, and a steadfast commitment to enhancing human mobility. The company first gained prominence with its Atalante X, a self-balancing rehabilitation exoskeleton. Atalante X, with its sophisticated gait control and dynamic balancing algorithms, allowed individuals with neurological impairments to practice walking in a safe and controlled clinical environment. Its widespread adoption in rehabilitation and research centers worldwide provided invaluable data and insights, proving the efficacy and potential of Wandercraft’s core self-balancing technology.
The success of Atalante X naturally led to the vision of extending this advanced mobility beyond the confines of the clinic. The development of Eve was born from this ambition, aiming to create a device that was not only robust and reliable but also intuitive enough for everyday personal use. The design challenges were significant, requiring a balance between advanced robotics, user-friendliness, and strict safety protocols to meet the stringent requirements of medical device regulation.
The path to FDA clearance involved rigorous testing and validation, culminating in a three-site clinical trial designed to assess Eve’s safety, function, and readiness for personal use. This comprehensive evaluation demonstrated that both users and their trained companions could effectively and safely operate the device in simulated real-world scenarios. The successful completion of these trials, coupled with extensive documentation, paved the way for the FDA’s decision, marking Eve as a pivotal advancement in the field of assistive robotics.
With the FDA clearance secured, Wandercraft has now set the stage for commercial availability. The September 17, 2026, launch event will not only unveil the device but also initiate a structured pathway for eligible individuals to access Eve. This includes a robust support system covering everything from initial clinical assessment and individualized fitting to comprehensive training, reimbursement assistance, and long-term device support, ensuring that this cutting-edge technology can genuinely transform lives.
Supporting Data: Building an Ecosystem of Access
The FDA clearance of Eve is underpinned by compelling clinical evidence and supported by a strategic framework designed to ensure broad access for eligible users. According to the Christopher & Dana Reeve Foundation, over five million people in the United States live with some form of paralysis, with hundreds of thousands affected by spinal cord injuries. For this population, the ability to stand and move upright carries profound physical, psychological, and social implications.
Clinical Rigor and Real-World Impact:
The foundation of Eve’s clearance rests on a comprehensive, three-site clinical trial conducted at leading institutions: the James J. Peters Department of Veterans Affairs Medical Center in the Bronx, NY; Kessler Foundation in West Orange, NJ; and Walk in New York in New York City, NY. This multi-center approach involved participants with a range of spinal cord injury severities and their companions, meticulously evaluating safety, functional performance, training efficacy, and readiness for personal use.
The trial protocol included structured training sessions, followed by a battery of functional, usability, and task-based assessments specifically designed to mimic everyday activities. The results were highly encouraging, demonstrating that both participants and their companions could proficiently learn to operate Eve and successfully complete tasks relevant to personal use. Key functional and usability endpoints, including measures of walking performance and activities of daily living, were met, validating the device’s potential for real-world integration.
Dr. Gail Forrest, Director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, underscored the significance of these findings: "What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities. The combination of functional performance, usability, and user-reported outcomes gives this technology substantial clinical relevance."
Beyond objective measures, participants reported a multitude of subjective improvements, highlighting the holistic benefits of upright mobility. These included enhancements in overall health status, psychological well-being, endurance during daily activities, and a reduction in lower-limb spasticity. Importantly, some users also reported improvements in sleep quality and in bladder and bowel function – often overlooked but critical aspects of daily health and dignity for individuals with spinal cord injuries. These subjective reports underscore the profound impact that renewed upright mobility can have on a user’s overall quality of life.
Navigating Reimbursement:
Recognizing that access to advanced technology hinges on affordability, Wandercraft has made significant investments in establishing a robust reimbursement pathway for Eve. Medicare has already established a reimbursement pathway for eligible personal exoskeleton users since 2024, under its Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) program, using billing code K1007. Wandercraft anticipates that Eve could become eligible for Medicare reimbursement within 60 to 90 days following its commercial launch. The company also plans to broaden patient access through private payers and other funding sources, ensuring that financial barriers do not impede qualified users from bringing Eve home.
To facilitate this complex process, Wandercraft has assembled a dedicated team of access specialists. This group will work directly with users and their care teams to navigate claim submissions, interpret coverage requirements, address reimbursement queries, and explore various financing options. This proactive approach underscores Wandercraft’s belief that technological innovation is only truly valuable when it is accessible to those who need it most.
Strategic Partnerships for Broad Reach:
To ensure a seamless transition from evaluation to at-home use, Wandercraft has forged strategic partnerships with a growing network of rehabilitation centers, complex rehabilitation technology (CRT) providers, and federal distribution partners. These collaborations are crucial for building the necessary infrastructure for clinical assessment, training, distribution, and long-term service.
- Walk US: This organization, with its flagship Walk in New York location and an upcoming Walk in Miami, specializes in neurorehabilitation using Atalante X. It will serve as a key partner for Eve evaluations, training, demonstrations, community education, and preparation for personal home use.
- National Seating & Mobility (NSM): As North America’s largest provider of complex rehabilitation technology, NSM has been designated Wandercraft’s exclusive CRT distribution partner for Eve. Leveraging its extensive network of over 180 locations across the United States and Canada, NSM will play a critical role in supporting evaluation, access, delivery, and ongoing service for Eve users.
- Good Shepherd Rehabilitation: This institution will serve as the exclusive Eve partner in Pennsylvania’s Lehigh Valley. Through Good Shepherd’s Hyland Center, eligible users and their companions will gain access to information and direct experience with the technology, with plans for additional access locations in the future.
- USVetServ: As a Service-Disabled Veteran-Owned Small Business, USVetServ will act as an authorized independent distributor of both Eve and Atalante X for the U.S. Department of Veterans Affairs (VA). This partnership reflects Wandercraft’s deep commitment to ensuring that veterans, who often face unique mobility challenges, have access to the most advanced assistive technologies available through VA Medical Centers and other facilities nationwide.
These partnerships collectively form a comprehensive ecosystem designed to translate FDA clearance into tangible, meaningful access, ensuring that eligible individuals receive the necessary clinical support, training, and logistical services to integrate Eve seamlessly into their lives.
Official Responses: Voices of Hope and Innovation
The FDA clearance has been met with resounding enthusiasm from Wandercraft’s leadership, test pilots, and clinical researchers, all of whom have played integral roles in Eve’s development and validation.
Matthieu Masselin, co-founder and CEO of Wandercraft, articulated the profound significance of this milestone: "FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible. Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio." His words underscore the company’s vision of creating a continuum of care, transitioning from controlled clinical environments to the freedom of personal use.
The personal impact of Eve is perhaps best captured by Caroline Laubach, a Wandercraft Test Pilot, whose lived experience offers a powerful testament to the device’s transformative potential. "For years, I experienced much of the world while seated," Laubach reflected. "Using Eve transformed ordinary moments in ways I never expected, like having conversations eye-to-eye whether seated or standing, getting a cup from the highest kitchen cabinet, and simply bringing a new type of confidence into my life." Her statement vividly illustrates the emotional and practical empowerment that Eve provides, moving beyond mere physical function to impact self-perception and social interaction.
Dr. Gail Forrest’s expert clinical perspective further validates Eve’s significance. Her comments on the clinical trial results highlight the rigorous methodology and the focus on real-world applicability. The emphasis on "how users and companions could safely integrate it into real-world activities" rather than just engineering performance, speaks to the practical, patient-centric design of Eve and the thoroughness of its evaluation.
Implications: A New Horizon for Independence
The FDA clearance of Wandercraft’s Eve exoskeleton carries far-reaching implications, not only for individuals with spinal cord injuries but also for the broader fields of healthcare, robotics, and assistive technology. This development signifies a major evolution, bringing sophisticated self-balancing technology out of controlled clinical environments and into the personal domain.
Enhanced Quality of Life and Well-being:
For eligible wheelchair users, Eve promises a dramatic enhancement in quality of life. The ability to stand and walk hands-free unlocks opportunities for greater independence in activities of daily living, fostering a sense of autonomy that can significantly impact psychological well-being. The reported improvements in physical health, such as reduced spasticity and better bowel/bladder function, coupled with enhanced social engagement from being at eye level, contribute to a more holistic sense of health and belonging. This extends beyond basic mobility, touching upon dignity, self-esteem, and the ability to participate more fully in family and community life.
Advancing Assistive Robotics:
Eve’s clearance also marks a significant milestone in the advancement of assistive robotics. It demonstrates the increasing sophistication and reliability of exoskeletal technology, moving towards more intuitive, user-friendly, and adaptable designs. The self-balancing capability, in particular, represents a crucial step, eliminating the need for external support and making the device more practical for personal use. This success will likely spur further innovation in the development of intelligent, adaptive robotics that can seamlessly integrate into human lives, offering solutions for a wider range of physical challenges.
A Model for Accessibility:
Wandercraft’s comprehensive approach to access, encompassing reimbursement assistance, dedicated specialists, and a broad network of partners, sets a new standard for bringing advanced medical technologies to market. By addressing the critical barriers of cost, training, and logistical support, the company is striving to ensure that Eve’s transformative potential is realized by those who can benefit most. This integrated model could serve as a blueprint for future developers of complex medical devices, emphasizing that innovation must be coupled with equitable access.
Future Prospects and Broader Impact:
Looking ahead, the success of Eve could pave the way for similar personal mobility solutions for individuals with other forms of paralysis or mobility impairments. It highlights a future where assistive devices are not merely functional but empowering, allowing users to reclaim aspects of their lives previously thought lost. The data gathered from Eve’s widespread use will also contribute invaluable knowledge to rehabilitation science, informing future therapeutic strategies and technological advancements.
In conclusion, Wandercraft’s Eve exoskeleton, with its FDA clearance, represents more than just a new medical device; it embodies a paradigm shift in personal mobility. It is a testament to human ingenuity and a commitment to breaking down barriers, promising eligible individuals the profound gift of hands-free upright movement and the extraordinary meaning it can bring to their everyday lives. As Eve prepares for its commercial launch, the world watches, anticipating a future where the promise of independence is increasingly within reach.
